Pill that mimics Viagra may slow Alzheimer’s progression by almost a third, study suggests

A global trial found that a pill which relaxes blood vessels and increases blood flow to the brain slowed cognitive decline in people with Alzheimer’s disease by nearly a third, with experts describing the results as 'very promising'. Alzheimer's is the most common form of dementia, currently incurable and projected to affect 153 million people by 2050.

A worldwide clinical study indicates that a pill that acts like Viagra — relaxing blood vessels and boosting blood flow to the brain — can slow the pace of cognitive decline in people with Alzheimer’s disease by almost a third.

Researchers reported that participants taking the medication showed substantially slower deterioration on cognitive measures compared with those who did not receive the drug. While the results are preliminary, independent experts described the findings as 'very promising' for a condition that currently has no cure.

Alzheimer’s disease is the leading cause of dementia and represents a growing global health burden. Current projections suggest the number of people living with dementia could reach about 153 million by 2050, underlining the urgency for effective treatments that can alter the course of the illness rather than only managing symptoms.

The medication tested works by widening blood vessels and increasing cerebral blood flow — a mechanism thought to help preserve brain function. The drug class involved is already used for other vascular conditions, which raises the possibility of repurposing existing medicines for Alzheimer’s treatment. However, researchers cautioned that these findings will need replication in larger and longer trials before they can change clinical practice.

Experts also stressed that slowing cognitive decline is not the same as a cure. Further research will be required to establish long-term benefits, optimal dosing, safety in older populations, and how the treatment interacts with other therapies for Alzheimer’s. If subsequent studies confirm the effect, the approach could represent an important advance in managing progression of the disease, offering more time and better quality of life for patients and caregivers.